GLP-1s to Enhance Lasting Optimal Weight

NCT06861439 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether GLP-1 medications can help people with obesity maintain a healthy weight by preserving muscle mass.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 40 people

Who can join Ages 65+ · all sexes

Timeline Started 2025-07 · est. completion 2026-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06861439 ↗

Description as written by the study sponsor.

The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period. Participants will take tirzepatide weekly, have clinic visits every 4 weeks, meet study doctor and registered dietitian every 4 weeks in person or video conference, attend group intervention sessions twice a month via video conference, weigh daily with a study-provided smart scale, keep a record of all foods and beverages consumed, and use a study-provided activity tracker to keep track of daily step counts.

Treatments tested

Tirzepatide also known as Zepbound Drug

Tirzepatide will be initiated at a dose of 2.5 mg weekly and increased as tolerated to 5 mg weekly at four weeks for the remainder of the 9-month intervention period. Participants who are unable to tolerate the 5 mg dose will be decreased to the 2.5 mg dose.

Main thing measured	Change in total body lean mass
Sponsor	Wake Forest University Health Sciences
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06861439 ↗